title: [Ethinylestradiol Following Everolimus plus Exemestane Was Effective in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer - A Case Report].
abstract: A 71-year-old woman diagnosed with left breast cancer underwent mastectomy and axillary dissection in 1987. Pathological findings showed invasive ductal carcinoma that was ER and PgR positive and HER2 negative.5 -FU and tamoxifen were administered for 2 years as adjuvant therapy.Bone metastasis was found in 2002, and endocrine therapy was started, using anastrozole, exemestane, letrozole, medroxyprogesterone acetate, and fulvestrant.However, liver, lung, pleural, penetiral, and lymph-node metastases were observed, and the following chemotherapy regimen was administered: CAF, capecitabine, paclitaxel, vinorelbine, gemcitabine, methotrexate plus mitomycin C, and eribulin.Then, estrogen therapy with ethinylestradiol( EE2)was started in December 2013.T he pleural effusion disappeared and the liver metastases were reduced.After 11 months of progression-free survival(PFS), regrowth of the liver metastases was seen.Thus, everolimus plus exemestane was administered, and approximately 8 months of PFS was obtained.Therefore, both EE2 and everolimus are effective therapy even for heavily pretreated metastatic breast cancer.
authors.affiliation: Dept. of Breast Surgery, Tokyo Women's Medical University, Medical Center East.
authors.forename: Aya
authors.initials: A
authors.lastname: Matsuoka
authors.forename: Akira
authors.initials: A
authors.lastname: Hirano
authors.forename: Akinori
authors.initials: A
authors.lastname: Hattori
authors.forename: Kaoru
authors.initials: K
authors.lastname: Ogura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Inoue
authors.forename: Hiroko
authors.initials: H
authors.lastname: Yukawa
authors.forename: Shiho
authors.initials: S
authors.lastname: Sakaguchi
authors.forename: Natsuko
authors.initials: N
authors.lastname: Tanaka
authors.forename: Asaka
authors.initials: A
authors.lastname: Kodera
authors.forename: Mari
authors.initials: M
authors.lastname: Kamimura
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Naritaka
authors.forename: Tadao
authors.initials: T
authors.lastname: Shimizu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015914:Estrogen Replacement Therapy; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D000068338:Everolimus / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008197:Lymph Node Excision; D008408:Mastectomy; D017698:Postmenopause
chemical_list: D004997:Ethinyl Estradiol; D000068338:Everolimus